<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136498</url>
  </required_header>
  <id_info>
    <org_study_id>1R34DA034612</org_study_id>
    <nct_id>NCT02136498</nct_id>
  </id_info>
  <brief_title>My Mobile Advice Program: A Randomized Pilot Feasibility Study</brief_title>
  <acronym>MyMAP</acronym>
  <official_title>Internet-based Medication Adherence Program for Nicotine Dependence Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the acceptability and feasibility of the
      proposed smoking cessation intervention (called MyMAP or My Mobile Advice Program).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will develop and pilot test a prototype of the MyMAP intervention.The
      intervention is designed to help smokers better manage issues known to reduce treatment
      adherence (withdrawal symptoms, medication side-effects, low motivation, and inadequate
      behavioral skills for medication adherence) and to facilitate greater communication between
      patients and providers so clinicians can provide appropriate oversight of medication use,
      intervene when medically necessary, and address patient concerns that may otherwise lead to
      non-adherence or early treatment termination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Point Prevalence Abstinence</measure>
    <time_frame>5 month follow-up</time_frame>
    <description>Self-report of no-smoking, even a puff during the last 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Varenicline Use</measure>
    <time_frame>5 mo follow-up</time_frame>
    <description>Number of days varenicline was used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>mHealth self-help + varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mHealth MyMAP program + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects &amp; secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Standard 12 week course of varenicline, provided in both arms</description>
    <arm_group_label>mHealth self-help + varenicline</arm_group_label>
    <arm_group_label>mHealth MyMAP program + varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-behavioral self-help</intervention_name>
    <description>Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.</description>
    <arm_group_label>mHealth self-help + varenicline</arm_group_label>
    <arm_group_label>mHealth MyMAP program + varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MyMAP (My Mobile Advice Program)</intervention_name>
    <description>Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor</description>
    <arm_group_label>mHealth MyMAP program + varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An invited member of Group Health, a health care system in the Pacific Northwest

          -  Plan to remain enrolled in Group Health for the next 6 months

          -  aged 18 - 65

          -  Eligible for smoking cessation treatment through Group Health insurance coverage

          -  smoke &gt;= 10 cigs a day

          -  speak and read in English

          -  willing to use varenicline and no contraindications for this medication

          -  ready to quit smoking

          -  have a smart phone with internet access

          -  willing to receive study texts and emails

          -  receive care at a Group Health clinic and have electronic medical records in this
             system

          -  fill prescriptions through the Group Health pharmacy

          -  agree to use birth control while taking study medication, if there is a risk of
             pregnancy

        Exclusion Criteria:

          -  lifetime history of dementia

          -  psychosis or bipolar disorder based on self-report or medical record review

          -  hearing, comprehension or visual limitations that preclude full study participation

          -  current use of other forms of tobacco

          -  any medical contraindication for varenicline use

          -  documented history of suicidal ideation/intent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer McClure, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Group Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheryl Catz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry An, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Group Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.2196/mhealth.6002</url>
    <description>Primary outcome paper</description>
  </link>
  <results_reference>
    <citation>McClure JB, Anderson ML, Bradley K, An LC, Catz SL. Evaluating an Adaptive and Interactive mHealth Smoking Cessation and Medication Adherence Program: A Randomized Pilot Feasibility Study. JMIR Mhealth Uhealth. 2016 Aug 3;4(3):e94. doi: 10.2196/mhealth.6002.</citation>
    <PMID>27489247</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <results_first_submitted>August 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2016</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>varenicline</keyword>
  <keyword>adherence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>mHealth Self-help + Varenicline</title>
          <description>Participants in the control arm received standard self-help education delivered via an mHealth program (accessible via smart phone) and a prescription for a standard 12 week course of varenicline.
Standard self-help included topics such as: how to make a quit plan, how to use varenicline, how to manage cravings to smoke, how tot manage nicotine withdrawal and medication side-effects, relapse prevention, etc.</description>
        </group>
        <group group_id="P2">
          <title>mHealth MyMAP + Varenicline</title>
          <description>Participants in the experimental arm received a mHealth program (accessible via smartphone) and a prescription for a standard 12 week course of varenicline.
The mHealth intervention included the same self-help content offered to controls + a) real-time, adaptively-tailored advice for managing nicotine withdrawal symptoms and medication side-effects and b) asynchronous secure messaging with a cessation counselor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>mHealth Self-help + Varenicline</title>
          <description>Participants in the control arm received standard self-help education delivered via an mHealth program (accessible via smart phone) and a prescription for a standard 12 week course of varenicline.
Standard self-help included topics such as: how to make a quit plan, how to use varenicline, how to manage cravings to smoke, how tot manage nicotine withdrawal and medication side-effects, relapse prevention, etc.</description>
        </group>
        <group group_id="B2">
          <title>mHealth MyMAP + Varenicline</title>
          <description>Participants in the experimental arm received a mHealth program (accessible via smartphone) and a prescription for a standard 12 week course of varenicline.
The mHealth intervention included the same self-help content offered to controls + a) real-time, adaptively-tailored advice for managing nicotine withdrawal symptoms and medication side-effects and b) asynchronous secure messaging with a cessation counselor.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="8.9"/>
                    <measurement group_id="B2" value="48.4" spread="8.4"/>
                    <measurement group_id="B3" value="49.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes smoked per day</title>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.9" spread="4.5"/>
                    <measurement group_id="B2" value="18.5" spread="9.1"/>
                    <measurement group_id="B3" value="17.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior use of varenicline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Used varenicline previously</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never used varenicline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Abstinence</title>
        <description>Self-report of no-smoking, even a puff during the last 7 days.</description>
        <time_frame>5 month follow-up</time_frame>
        <population>Intent to treat analyses with missing cases imputed as smokers.</population>
        <group_list>
          <group group_id="O1">
            <title>mHealth Self-help + Varenicline</title>
            <description>Participants in the control arm received standard self-help education delivered via an mHealth program (accessible via smart phone) and a prescription for a standard 12 week course of varenicline.
Standard self-help included topics such as: how to make a quit plan, how to use varenicline, how to manage cravings to smoke, how tot manage nicotine withdrawal and medication side-effects, relapse prevention, etc.</description>
          </group>
          <group group_id="O2">
            <title>Augmented mHealth Self-help + Varenicline</title>
            <description>Participants in the experimental arm received a mHealth program (accessible via smartphone) and a prescription for a standard 12 week course of varenicline.
The mHealth intervention included the same self-help content offered to controls + a) real-time, adaptively-tailored advice for managing nicotine withdrawal symptoms and medication side-effects and b) asynchronous secure messaging with a cessation counselor.</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence</title>
          <description>Self-report of no-smoking, even a puff during the last 7 days.</description>
          <population>Intent to treat analyses with missing cases imputed as smokers.</population>
          <units>Percentage of people not smoking</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Varenicline Use</title>
        <description>Number of days varenicline was used</description>
        <time_frame>5 mo follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>mHealth Self-help + Varenicline</title>
            <description>Participants in the control arm received standard self-help education delivered via an mHealth program (accessible via smart phone) and a prescription for a standard 12 week course of varenicline.
Standard self-help included topics such as: how to make a quit plan, how to use varenicline, how to manage cravings to smoke, how tot manage nicotine withdrawal and medication side-effects, relapse prevention, etc.</description>
          </group>
          <group group_id="O2">
            <title>Augmented mHealth Self-help + Varenicline</title>
            <description>Participants in the experimental arm received a mHealth program (accessible via smartphone) and a prescription for a standard 12 week course of varenicline.
The mHealth intervention included the same self-help content offered to controls + a) real-time, adaptively-tailored advice for managing nicotine withdrawal symptoms and medication side-effects and b) asynchronous secure messaging with a cessation counselor.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Varenicline Use</title>
          <description>Number of days varenicline was used</description>
          <units>Mean number of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="28.9"/>
                    <measurement group_id="O2" value="46" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored throughout the study period (~ 6 months).</time_frame>
      <desc>Medication side-effects/nicotine withdrawal symptoms (adverse events) were assessed at each follow-up using a standard checklist of events, resulting in a high number of reports in both arms. Experimental participants were also asked to report ongoing side-effects and symptoms to receive tailored treatment advice, increasing reports in this arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>mHealth Self-help + Varenicline</title>
          <description>Participants in the control arm received standard self-help education delivered via an mHealth program (accessible via smart phone) and a prescription for a standard 12 week course of varenicline.
Standard self-help included topics such as: how to make a quit plan, how to use varenicline, how to manage cravings to smoke, how tot manage nicotine withdrawal and medication side-effects, relapse prevention, etc.</description>
        </group>
        <group group_id="E2">
          <title>mHealth MyMAP + Varenicline</title>
          <description>Participants in the experimental arm received a mHealth program (accessible via smartphone) and a prescription for a standard 12 week course of varenicline.
The mHealth intervention included the same self-help content offered to controls + a) real-time, adaptively-tailored advice for managing nicotine withdrawal symptoms and medication side-effects and b) asynchronous secure messaging with a cessation counselor.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Passive suicidal ideation without intent</sub_title>
                <description>Participant reported passive suicidal ideation (without intent) on his wedding anniversary from his estranged wife. Participant had a history of psychiatric issues and was not taking varenicline at the time.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarhhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" events="33" subjects_affected="15" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>stomach pain or vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vivid or unusual dreams</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E2" events="36" subjects_affected="19" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E2" events="23" subjects_affected="12" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Insomnia or trouble sleeping</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rapid heart beat or chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger or irritability</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E2" events="24" subjects_affected="15" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Confusion/difficulty concentrating</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Craving to smoke</sub_title>
                <counts group_id="E1" events="40" subjects_affected="22" subjects_at_risk="33"/>
                <counts group_id="E2" events="74" subjects_affected="30" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Memory problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation of this pilot study is the small sample size, which prevents definitive conclusions about the efficacy of the MyMAP intervention.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principle Investigator</name_or_title>
      <organization>Group Health Research Institute</organization>
      <phone>206-287-2737</phone>
      <email>mcclure.j@ghc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

